What to know about taking Wegovy before you decide

How the dose schedule actually works, and why it matters for your expectations

Starting Wegovy at 0.25mg is not a therapeutic dose in the usual sense. The body needs time to adjust to the medicine, and the graduated titration (0.25mg, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg) exists largely to reduce gastrointestinal discomfort rather than to build effect slowly from nothing. Appetite suppression increases meaningfully as the dose rises.

The MHRA also approved a higher 7.2mg maintenance dose: first as three simultaneous 2.4mg injections each week, then as a dedicated single-dose 7.2mg pen confirmed on 14 April 2026. Trial data reported around 20.7% average weight loss over 72 weeks at this dose, which narrows the gap considerably with tirzepatide's results. Whether the 7.2mg pen is the right target for any individual patient is a clinical decision, not a default. The semaglutide overview on our site sets out the full dose pathway in plain terms.

In the STEP 1 trial (published in the New England Journal of Medicine) participants using semaglutide 2.4mg lost around 15% of body weight on average over 68 weeks. That is a clinical-trial average, not a promise; individual results depend on many factors, including starting weight, diet, activity and how well the dose is tolerated. If you want a fuller picture before starting, there are several important things to know about Wegovy that bring together the evidence and practical context in one place, and our dedicated guide covers what you need to know about Wegovy too, via our guide covering what you need to know about Wegovy.

Side effects: what to expect, and what needs urgent attention

Most people taking Wegovy notice some digestive symptoms, particularly in the first few weeks and after each dose step up. Nausea is the most reported; others include loose stools, constipation, burping, stomach discomfort and, less commonly, vomiting. For most people these settle as the body adapts. Eating smaller meals, avoiding fatty food in the first weeks, and staying hydrated all help, a question our prescribers hear regularly is whether the nausea goes away, and for most people taking things slowly at each dose step, it does.

Some symptoms need prompt medical attention. Severe, persistent abdominal pain that radiates toward the back (with or without vomiting) should not be waited out; the MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines. Symptoms of gallbladder problems, dehydration from prolonged vomiting or diarrhoea, or any allergic reaction also warrant immediate contact with a doctor or 111. Side effects can be reported directly to the MHRA via the Yellow Card scheme at that same link.

Wegovy is not recommended during pregnancy, while trying to conceive, or when breastfeeding. Under-18s are not a licensed population. Personal and family medical history (including thyroid conditions, a history of pancreatitis, or certain GI problems) is part of what the prescriber reviews before approving treatment.

Storage, routine, and the practical detail people often miss

The pen lives in the fridge, ideally somewhere with a stable 2–8°C temperature. There is a limited room-temperature window for travel or days out; the exact duration is in the Patient Information Leaflet that comes with your pen, and that is the figure to follow rather than any general estimate. Once you're used to the routine, Sunday evening before bed or Monday morning becomes the natural injection moment, consistency with the day of the week matters more than the time of day.

Injection sites (abdomen, outer thigh, upper arm) should be rotated to avoid skin changes at any single spot. If you are also using oral contraceptives, the prescriber may advise an additional non-oral method of contraception during a dose step-up period because GLP-1 medicines slow gastric emptying, which can affect absorption of oral medicines. NHS guidance is specific on this point; it is worth raising it at the consultation if relevant to you. The practical guide to taking Wegovy covers injection technique and routine in more detail.

Eligibility, cost context, and how to move forward

The licensed eligibility for Wegovy in private practice mirrors the SmPC: adults with a BMI of 30 or higher, or 27–29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is not the whole picture; the prescriber looks at your health history, current medicines and any contraindications.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), which sets a two-year maximum treatment duration and a multidisciplinary care requirement. Waiting lists can be long. Private treatment through a regulated online pharmacy means no referral and no waiting list, subject to clinical suitability assessed at the point of consultation. If cost is part of your thinking, the Wegovy price comparison page gives a factual breakdown of what a legitimate private prescription includes and why the headline figure sometimes differs between providers.

Semaglutide is licensed for weight management as Wegovy only. Ozempic is semaglutide prescribed for type 2 diabetes and is not a weight-management route, if you have seen it suggested elsewhere, the semaglutide explainer covers that distinction clearly.